ACRV Stock Catalyst: Acrivon Therapeutics Announced Positive Clinical Data for ACR-368 and ACR-2316, Nominated ACR-6840 as Next Development Candidate

Jan 7, 2026 · 6:58pm ET

Company revealed results from Phase 2b trial and initial clinical data.

Max move

+38.7%

High of day $4.09

Sparker timei

6:58pm ET

ACRV · Jan 7, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Acrivon Therapeutics, Inc. announced on 2026-01-08 Acrivon Therapeutics announced positive clinical data for ACR-368 Phase 2b endometrial cancer trial, initial ACR-2316 clinical data, and nominated ACR-6840 as next AP3-enabled development candidate targeting CDK11.

44% ORR in subjects with ≤2 prior lines of therapy. 67% cORR in BM+ subjects with serous EC. 9/20 subjects showed tumor shrinkage at ≥120 mg dose level. The announcement cited 39% overall response rate (ORR).

Acrivon Therapeutics, Inc. Common Stock has a free float of 16,857,100 shares and 31,555,100 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time ACRV sparks.

Download Sniper App →

Catch the next ACRV-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →